Cite

    Jabbour, E. et al. (2022). Blinatumomab is associated with favorable outcomes in patients with B‐cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10−4 and higher. American journal of hematology. 97 (9), pp. 1135-1141. [Online].